Bio-Techne Corp TECH

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
78/100
Strong

About Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, … Full TECH analysis →

Competitive advantage assessment

Key strengths

  • ROIC Sustainably Above Peers ROIC at 84.0th percentile exceeds peers and WACC, demonstrating superior capital allocation.
  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.99), demonstrating pricing resilience across cycles.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
76

Where TECH ranks in Biotechnology

Bio-Techne Corp ranks #15 of 713 scored companies in Biotechnology by moat score — the top 2%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near TECH in Biotechnology
# Company Moat score Rating
11 Krystal Biotech, Inc. KRYS 79/100 Strong
12 Galapagos NV GLPG 79/100 Strong
13 Corcept Therapeutics Incorporat CORT 78/100 Strong
14 Regeneron Pharmaceuticals, Inc. REGN 78/100 Strong
15 Bio-Techne Corp TECH 78/100 Strong
16 Halozyme Therapeutics, Inc. HALO 78/100 Strong
17 BioMarin Pharmaceutical Inc. BMRN 78/100 Strong
18 Q32 Bio Inc. QTTB 77/100 Strong
19 Aurinia Pharmaceuticals Inc AUPH 77/100 Strong

See every Biotech / Pre-Revenue company ranked by moat score →

How TECH scores on the Corporate Default defenses

Pricing Power

Score 76 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 90 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 94 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 87 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 66 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 56 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding TECH's moat

What is Bio-Techne Corp's moat score?

Bio-Techne Corp (TECH) scores 78 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as strong. It ranks #15 of 713 scored companies in Biotechnology, the top 2%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (94/100) and its weakest is Scale & Market Position (56/100).

How does Bio-Techne Corp compare with other Biotechnology companies?

Bio-Techne Corp ranks #15 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Regeneron Pharmaceuticals, Inc. (REGN) at 78 just above it and Halozyme Therapeutics, Inc. (HALO) at 78 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Bio-Techne Corp scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Bio-Techne Corp?

The Corporate Default template measures 6 defenses, and TECH scores: Pricing Power (76), Cost Advantage (90), Customer Stickiness (94), Capital Efficiency (87), Resilience (66), Scale & Market Position (56). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000